PureTech Health plc (NASDAQ:PRTC - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $22.15, but opened at $21.00. PureTech Health shares last traded at $21.00, with a volume of 600 shares trading hands.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on PRTC shares. Leerink Partners assumed coverage on PureTech Health in a research note on Monday, September 9th. They set an "outperform" rating and a $45.00 target price for the company. Leerink Partnrs raised shares of PureTech Health to a "strong-buy" rating in a research report on Monday, September 9th.
Check Out Our Latest Stock Report on PRTC
PureTech Health Trading Down 1.6 %
The firm's fifty day moving average price is $21.21 and its two-hundred day moving average price is $22.49.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC acquired a new stake in shares of PureTech Health plc (NASDAQ:PRTC - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 302,000 shares of the company's stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned approximately 1.26% of PureTech Health as of its most recent SEC filing. 0.04% of the stock is owned by institutional investors.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Featured Articles
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
